FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

James Hagan

Research Profile

Living Beings

Chemicals & Drugs

Concepts & Ideas

Drug Dose Response Relationship

Anatomy

Activities & Behaviors

Procedures

Radioligand Assay

Co-author Network

Publications

TOP 3
A R Pickles; D N C Jones; James Hagan; CA Hendrie
Short-term individual housing induced social deficits in female Mongolian gerbils: attenuation by chronic but not acute imipramine.
David R Thomas; Adeshola Dada; Gareth A Jones; Rudolf A Deisz; Sylvain Gigout; Christopher J Langmead; Tim D Werry; Nicola Hendry; James Hagan; Ceri H Davies; Jeannette M Watson
N-desmethylclozapine (NDMC) is an antagonist at the human native muscarinic M(1) receptor.
Lee A Dawson; Christopher J Langmead; Adeshola Dada; Jeannette M Watson; Zining Wu; Raúl de la Flor; Gareth A Jones; Jane E Cluderay; Eric Southam; Graham S Murkitt; Mark D Hill; Declan N C Jones; Ceri H Davies; James Hagan; Paul W Smith
In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of James Hagan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: A R Pickles; D N C Jones; James Hagan; CA Hendrie
Short-term individual housing induced social deficits in female Mongolian gerbils: attenuation by chronic but not acute imipramine.
Neuropharmacology 2012;62(5-6):1993-8.
2010: David R Thomas; Adeshola Dada; Gareth A Jones; Rudolf A Deisz; Sylvain Gigout; Christopher J Langmead; Tim D Werry; Nicola Hendry; James Hagan; Ceri H Davies; Jeannette M Watson
N-desmethylclozapine (NDMC) is an antagonist at the human native muscarinic M(1) receptor.
Neuropharmacology 2010;58(8):1206-14.
2010: Lee A Dawson; Christopher J Langmead; Adeshola Dada; Jeannette M Watson; Zining Wu; Raúl de la Flor; Gareth A Jones; Jane E Cluderay; Eric Southam; Graham S Murkitt; Mark D Hill; Declan N C Jones; Ceri H Davies; James Hagan; Paul W Smith
In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics.
European journal of pharmacology 2010;627(1-3):106-14.
2010: Dinko Relkovic; Christine M Doe; Trevor Humby; Karen A Johnstone; James L Resnick; Anthony J Holland; James Hagan; Lawrence S Wilkinson; Anthony R Isles
Behavioural and cognitive abnormalities in an imprinting centre deletion mouse model for Prader-Willi syndrome.
The European journal of neuroscience 2010;31(1):156-64.
2009: P R Maycox; F Kelly; A Taylor; S Bates; J Reid; R Logendra; M R Barnes; C Larminie; N Jones; M Lennon; C Davies; James Hagan; C A Scorer; C Angelinetta; M T Akbar; T Akbar; S Hirsch; A M Mortimer; Thomas R E Barnes; Jackie de Belleroche
Analysis of gene expression in two large schizophrenia cohorts identifies multiple changes associated with nerve terminal function.
Molecular psychiatry 2009;14(12):1083-94.
2009: Massimiliano Bianchi; Kevin C F Fone; Ajit J Shah; Alan R Atkins; Lee A Dawson; Christian A Heidbreder; James Hagan; Charles A Marsden
Chronic fluoxetine differentially modulates the hippocampal microtubular and serotonergic system in grouped and isolation reared rats.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2009;19(11):778-90.
2009: Hasib Salah-Uddin; Elizabeth Scarr; Geoffrey Pavey; Kriss Harris; James Hagan; Brian Dean; R A John Challiss; Jeannette M Watson
Altered M(1) muscarinic acetylcholine receptor (CHRM1)-Galpha(q/11) coupling in a schizophrenia endophenotype.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2009;34(9):2156-66.
2009: Massimiliano Bianchi; Ajit J Shah; Kevin C F Fone; Alan R Atkins; Lee A Dawson; Christian A Heidbreder; Mark E Hows; James Hagan; Charles A Marsden
Fluoxetine administration modulates the cytoskeletal microtubular system in the rat hippocampus.
Synapse (New York, N.Y.) 2009;63(4):359-64.
2008: C J Langmead; N E Austin; C L Branch; Jon Brown; K A Buchanan; C H Davies; I T Forbes; V A H Fry; James Hagan; H J Herdon; G A Jones; R Jeggo; J N C Kew; A Mazzali; R Melarange; N Patel; J Pardoe; A D Randall; C Roberts; A Roopun; K R Starr; A Teriakidis; M D Wood; M Whittington; Z Wu; J Watson
Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1.
British journal of pharmacology 2008;154(5):1104-15.
2008: Andrew G Foley; Warren D Hirst; Helen C Gallagher; Claire Barry; James Hagan; Neil Upton; Frank S Walsh; A Jackie Hunter; Ciaran M Regan
The selective 5-HT6 receptor antagonists SB-271046 and SB-399885 potentiate NCAM PSA immunolabeling of dentate granule cells, but not neurogenesis, in the hippocampal formation of mature Wistar rats.
Neuropharmacology 2008;54(8):1166-74.
2008: Hasib Salah-Uddin; David R Thomas; Ceri H Davies; James Hagan; Martyn D Wood; Jeannette M Watson; R A John Challiss
Pharmacological assessment of m1 muscarinic acetylcholine receptor-gq/11 protein coupling in membranes prepared from postmortem human brain tissue.
The Journal of pharmacology and experimental therapeutics 2008;325(3):869-74.
2007: Fabrizio Micheli; Giorgio Bonanomi; Frank E Blaney; Simone Braggio; Anna Maria Capelli; Anna Checchia; Ornella Curcuruto; Federica Damiani; Romano Di Fabio; Daniele Donati; Gabriella Gentile; Andy Gribble; Dieter Hamprecht; Giovanna Tedesco; Silvia Terreni; Luca Tarsi; Andrew Lightfoot; Geoff Stemp; Gregor Macdonald; Alex Smith; Michela Pecoraro; Marcella Petrone; Ornella Perini; Jacqui Piner; Tino Rossi; Angela Worby; Maria Pilla; Enzo Valerio; Cristiana Griffante; Manolo Mugnaini; Martyn Wood; Claire Scott; Michela Andreoli; laurent lacroix; Adam Schwarz; Alessandro Gozzi; Angelo Bifone; Charles R Ashby; James Hagan; Christian Heidbreder
1,2,4-triazol-3-yl-thiopropyl-tetrahydrobenzazepines: a series of potent and selective dopamine D(3) receptor antagonists.
Journal of medicinal chemistry 2007;50(21):5076-89.
2007: Kathryn R Starr; Gary W Price; Jeannette M Watson; Peter J Atkinson; Roberto Arban; Sergio Melotto; Lee A Dawson; James Hagan; Neil Upton; Mark S Duxon
SB-649915-B, a novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2007;32(10):2163-72.
2007: Youichirou Ootsuka; Christian Heidbreder; James Hagan; William W Blessing
Dopamine D2 receptor stimulation inhibits cold-initiated thermogenesis in brown adipose tissue in conscious rats.
Neuroscience 2007;147(1):127-35.
2007: Zoë A Hughes; Kathryn R Starr; Claire M Scott; Michael J Newson; Trevor Sharp; Jeannette M Watson; James Hagan; Lee A Dawson
Simultaneous blockade of 5-HT1A/B receptors and 5-HT transporters results in acute increases in extracellular 5-HT in both rats and guinea pigs: in vivo characterization of the novel 5-HT1A/B receptor antagonist/5-HT transport inhibitor SB-649915-B.
Psychopharmacology 2007;192(1):121-33.
2007: Vincenzo Garzya; Ian T Forbes; Andrew D Gribble; Michael S Hadley; Andrew P Lightfoot; Andrew H Payne; Alexander B Smith; Sara E Douglas; David G Cooper; Ian G Stansfield; Malcom Meeson; Emma E Dodds; Declan N C Jones; Martyn Wood; Charlie Reavill; Carol A Scorer; Angela Worby; Graham Riley; Peter Eddershaw; Chris Ioannou; Daniele Donati; James Hagan; Emiliangelo A Ratti
Studies towards the identification of a new generation of atypical antipsychotic agents.
Bioorganic & medicinal chemistry letters 2007;17(2):400-5.
2006: Massimiliano Bianchi; K F C Fone; N Azmi; Christian Heidbreder; James Hagan; Charles A Marsden
Isolation rearing induces recognition memory deficits accompanied by cytoskeletal alterations in rat hippocampus.
The European journal of neuroscience 2006;24(10):2894-902.
2006: David R Thomas; Ellen M Soffin; Claire Roberts; James N C Kew; Raul M de la Flor; Lee A Dawson; Victoria A Fry; Sara A Coggon; Stefania Faedo; Philip D Hayes; David F Corbett; Ceri H Davies; James Hagan
SB-699551-A (3-cyclopentyl-N-[2-(dimethylamino)ethyl]-N-[(4'-{[(2-phenylethyl)amino]methyl}-4-biphenylyl)methyl]propanamide dihydrochloride), a novel 5-ht5A receptor-selective antagonist, enhances 5-HT neuronal function: Evidence for an autoreceptor role for the 5-ht5A receptor in guinea pig brain.
Neuropharmacology 2006;51(3):566-77.
2006: Helge A Slotten; Mikhail Kalinichev; James Hagan; Charles A Marsden; Kevin C F Fone
Long-lasting changes in behavioural and neuroendocrine indices in the rat following neonatal maternal separation: gender-dependent effects.
Brain research 2006;1097(1):123-32.
2006: Lee A Dawson; Zoë A Hughes; Kathryn R Starr; James D Storey; Letizia Bettelini; Fabrizio Bacchi; Roberto Arban; Alessandro Poffe; Sergio Melotto; James Hagan; Gary W Price
Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity.
Neuropharmacology 2006;50(8):975-83.
2006: Claire Scott; Christopher J Langmead; Kirsten L Clarke; Paul A Wyman; Paul W Smith; Kathryn R Starr; Lee A Dawson; Gary W Price; James Hagan; Jeannette Watson
SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'methyl-4'-(5-methyl-1,2,3-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): a novel, potent and selective 5-HT1B receptor antagonist.
Neuropharmacology 2006;50(8):984-90.
2006: Claire Scott; Ellen M Soffin; Matthew Hill; Peter J Atkinson; Christopher J Langmead; Paul B Wren; Stefania Faedo; Laurie J Gordon; Gary W Price; Steven M Bromidge; Christopher N Johnson; James Hagan; Jeannette Watson
SB-649915, a novel, potent 5-HT1A and 5-HT1B autoreceptor antagonist and 5-HT re-uptake inhibitor in native tissue.
European journal of pharmacology 2006;536(1-2):54-61.
2005: Massimiliano Bianchi; James Hagan; Christian Heidbreder
Neuronal plasticity, stress and depression: involvement of the cytoskeletal microtubular system?
Current drug targets. CNS and neurological disorders 2005;4(5):597-611.
2005: James Hagan; Declan N C Jones
Predicting drug efficacy for cognitive deficits in schizophrenia.
Schizophrenia bulletin 2005;31(4):830-53.
2005: Paula D Hatcher; Verity J Brown; David Scott Tait; Simon Bate; Philip Overend; James Hagan; Declan N C Jones
5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats.
Psychopharmacology 2005;181(2):253-9.
2005: Claire Roberts; James Hagan; Gerd D Bartoszyk; James N C Kew
Effect of vilazodone on 5-HT efflux and re-uptake in the guinea-pig dorsal raphe nucleus.
European journal of pharmacology 2005;517(1-2):59-63.
2005: Christian A Heidbreder; Eliot L Gardner; Zheng-Xiong Xi; Panayotis K Thanos; Manolo Mugnaini; James Hagan; Charles R Ashby
The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.
Brain research. Brain research reviews 2005;49(1):77-105.
2005: Zoë A Hughes; Kathryn R Starr; Christopher J Langmead; Matthew Hill; Gerd D Bartoszyk; James Hagan; Derek N Middlemiss; Lee A Dawson
Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.
European journal of pharmacology 2005;510(1-2):49-57.
2005: Christian A Heidbreder; James Hagan
Novel pharmacotherapeutic approaches for the treatment of drug addiction and craving.
Current opinion in pharmacology 2005;5(1):107-18.
2004: Jane E Gartlon; Philip G Szekeres; Mark A Pullen; Henry M Sarau; Nambi Aiyar; Usman Shabon; David Michalovich; Klaudia Steplewski; Cathy Ellis; Nabil A Elshourbagy; Mark S Duxon; Tracey E Ashmeade; David C Harrison; Paul R Murdock; Shelagh Wilson; Abdel Ennaceur; Alan R Atkins; Christian A Heidbreder; James Hagan; A Jackie Hunter; Declan N C Jones
Localisation of NMU1R and NMU2R in human and rat central nervous system and effects of neuromedin-U following central administration in rats.
Psychopharmacology 2004;177(1-2):1-14.
2004: Michael J Jackson; Ghassan Al-Barghouthy; R K B Pearce; Lance Smith; James Hagan; Peter Jenner
Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets.
Pharmacology, biochemistry, and behavior 2004;79(3):391-400.
2004: Zheng-Xiong Xi; Jeremy Gilbert; Arlene C Campos; Nicole Kline; Charles R Ashby; James Hagan; Christian A Heidbreder; Eliot L Gardner
Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats.
Psychopharmacology 2004;176(1):57-65.
2004: Jane E Gartlon; Tracey E Ashmeade; Mark S Duxon; James Hagan; Declan N C Jones
Urotensin-II, a neuropeptide ligand for GPR14, induces c-fos in the rat brain.
European journal of pharmacology 2004;493(1-3):95-8.
2004: Arif Siddiqui; Mahmoud Abu-Amara; Cyrielle Aldairy; James Hagan; Catherine Wilson
5-HT7 receptor subtype as a mediator of the serotonergic regulation of luteinizing hormone release in the zona incerta.
European journal of pharmacology 2004;491(1):77-84.
2004: Yoshio Minabe; Yukihiko Shirayama; Kenji Hashimoto; Carol Routledge; James Hagan; Charles R Ashby
Effect of the acute and chronic administration of the selective 5-HT6 receptor antagonist SB-271046 on the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study.
Synapse (New York, N.Y.) 2004;52(1):20-8.
2004: David R Thomas; James Hagan
5-HT7 receptors.
Current drug targets. CNS and neurological disorders 2004;3(1):81-90.
2004: laurent lacroix; Lee A Dawson; James Hagan; Christian A Heidbreder
5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex.
Synapse (New York, N.Y.) 2004;51(2):158-64.
2004: Andrew G Foley; Keith J Murphy; Warren D Hirst; Helen C Gallagher; James Hagan; Neil Upton; Frank S Walsh; Ciaran M Regan
The 5-HT(6) receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2004;29(1):93-100.
2003: Gregor Macdonald; Clive L Branch; Michael S Hadley; Christopher N Johnson; David J Nash; Alexander B Smith; Geoffrey Stemp; Kevin M Thewlis; Antonio K K Vong; Nigel E Austin; Phillip Jeffrey; Kim Y Winborn; Izzy Boyfield; James Hagan; Derek N Middlemiss; Charlie Reavill; Graham J Riley; Jeannette M Watson; Martyn Wood; Steve G Parker; Charles R Ashby Jr
Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist.
Journal of medicinal chemistry 2003;46(23):4952-64.
2003: CA Hendrie; A R Pickles; Mark S Duxon; G Riley; James Hagan
Effects of fluoxetine on social behaviour and plasma corticosteroid levels in female Mongolian gerbils.
Behavioural pharmacology 2003;14(7):545-50.
2003: Michela Andreoli; Michela Tessari; Maria Pilla; Enzo Valerio; James Hagan; Christian A Heidbreder
Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2003;28(7):1272-80.
2003: David R Thomas; Sergio Melotto; Mario Massagrande; Andrew D Gribble; Phillip Jeffrey; Alexander J Stevens; Nigel J Deeks; Peter J Eddershaw; Susan H Fenwick; Graham Riley; Tania O Stean; Claire M Scott; Matthew J Hill; Derek N Middlemiss; James Hagan; Gary W Price; Ian T Forbes
SB-656104-A, a novel selective 5-HT7 receptor antagonist, modulates REM sleep in rats.
British journal of pharmacology 2003;139(4):705-14.
2003: Charles R Ashby; Mousumi Paul; Eliot L Gardner; Christian A Heidbreder; James Hagan
Acute administration of the selective D3 receptor antagonist SB-277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats.
Synapse (New York, N.Y.) 2003;48(3):154-6.
2003: laurent lacroix; Mark E P Hows; Ajit J Shah; James Hagan; Christian A Heidbreder
Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2003;28(5):839-49.
2003: Patricia Di Ciano; Rachel J Underwood; James Hagan; Barry J Everitt
Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2003;28(2):329-38.
2002: Stanislav R Vorel; Charles R Ashby; Mousumi Paul; Xinhe Liu; Robert Hayes; James Hagan; Derek N Middlemiss; Geoffrey Stemp; Eliot L Gardner
Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2002;22(21):9595-603.
2002: Catherine H Gill; Ellen M Soffin; James Hagan; Ceri H Davies
5-HT7 receptors modulate synchronized network activity in rat hippocampus.
Neuropharmacology 2002;42(1):82-92.
2001: Derek C Rogers; James Hagan
5-HT6 receptor antagonists enhance retention of a water maze task in the rat.
Psychopharmacology 2001;158(2):114-9.
2001: Jonathan P Hatcher; Declan N C Jones; Derek C Rogers; Paula D Hatcher; Charlie Reavill; James Hagan; A Jackie Hunter
Development of SHIRPA to characterise the phenotype of gene-targeted mice.
Behavioural brain research 2001;125(1-2):43-7.
2001: Christian A Heidbreder; Richard M Foxton; Jackie Cilia; Zoë A Hughes; Ajit J Shah; Alan R Atkins; A Jackie Hunter; James Hagan; Declan N C Jones
Increased responsiveness of dopamine to atypical, but not typical antipsychotics in the medial prefrontal cortex of rats reared in isolation.
Psychopharmacology 2001;156(2-3):338-51.
2001: Jackie Cilia; Charlie Reavill; James Hagan; Declan N C Jones
Long-term evaluation of isolation-rearing induced prepulse inhibition deficits in rats.
Psychopharmacology 2001;156(2-3):327-37.
2001: Jane E Gartlon; F Parker; David C Harrison; Stephen Douglas; Tracey E Ashmeade; Graham J Riley; Zoë A Hughes; SG Taylor; Richard Munton; James Hagan; J A Hunter; Declan N C Jones
Central effects of urotensin-II following ICV administration in rats.
Psychopharmacology 2001;155(4):426-33.
2001: Jackie Cilia; DC Piper; Neil Upton; James Hagan
Clozapine enhances breakpoint in common marmosets responding on a progressive ratio schedule.
Psychopharmacology 2001;155(2):135-43.
2001: Claire Roberts; L Allen; Christopher J Langmead; James Hagan; Derek N Middlemiss; Gary W Price
The effect of SB-269970, a 5-HT(7) receptor antagonist, on 5-HT release from serotonergic terminals and cell bodies.
British journal of pharmacology 2001;132(7):1574-80.
2001: Declan N C Jones; Jane E Gartlon; F Parker; SG Taylor; Carol Routledge; P Hemmati; Richard Munton; Tracey E Ashmeade; Jonathan P Hatcher; A Johns; Rod A Porter; James Hagan; A Jackie Hunter; Neil Upton
Effects of centrally administered orexin-B and orexin-A: a role for orexin-1 receptors in orexin-B-induced hyperactivity.
Psychopharmacology 2001;153(2):210-8.
2000: Charles R Ashby; Y Minabe; Geoffrey Stemp; James Hagan; Derek N Middlemiss
Acute and chronic administration of the selective D(3) receptor antagonist SB-277011-A alters activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study.
The Journal of pharmacology and experimental therapeutics 2000;294(3):1166-74.
2000: Charlie Reavill; SG Taylor; Martyn D Wood; Tracey E Ashmeade; Nigel E Austin; KY Avenell; Izzy Boyfield; Clive L Branch; Jackie Cilia; Martin Coldwell; Michael S Hadley; A Jackie Hunter; Phillip Jeffrey; FR Jewitt; Christopher N Johnson; Declan N C Jones; Andrew D Medhurst; Derek N Middlemiss; David J Nash; Graham J Riley; Carol Routledge; Geoffrey Stemp; Kevin M Thewlis; Brenda K Trail; Antonio K K Vong; James Hagan
Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.
The Journal of pharmacology and experimental therapeutics 2000;294(3):1154-65.
2000: Claire Roberts; Paula D Hatcher; James Hagan; Nigel E Austin; Phillip Jeffrey; Paul A Wyman; Laramie M Gaster; Carol Routledge; Derek N Middlemiss
The effect of SB-236057-A, a selective 5-HT1B receptor inverse agonist, on in vivo extracellular 5-HT levels in the freely-moving guinea-pig.
Naunyn-Schmiedeberg's archives of pharmacology 2000;362(2):177-83.
2000: Derek C Rogers; Brenda Costall; A M Domeney; P A Gerrard; M Greener; M E Kelly; James Hagan; A Jackie Hunter
Anxiolytic profile of ropinirole in the rat, mouse and common marmoset.
Psychopharmacology 2000;151(1):91-7.
2000: James Hagan; Gary W Price; Phillip Jeffrey; Nigel J Deeks; Tania O Stean; DC Piper; Martin I Smith; Neil Upton; Andrew D Medhurst; Derek N Middlemiss; Graham J Riley; Peter J Lovell; Steven M Bromidge; David R Thomas
Characterization of SB-269970-A, a selective 5-HT(7) receptor antagonist.
British journal of pharmacology 2000;130(3):539-48.
2000: Geoffrey Stemp; Tracey E Ashmeade; Clive L Branch; Michael S Hadley; A Jackie Hunter; Christopher N Johnson; David J Nash; Kevin M Thewlis; Antonio K K Vong; Nigel E Austin; Phillip Jeffrey; KY Avenell; Izzy Boyfield; James Hagan; Derek N Middlemiss; Charlie Reavill; Graham J Riley; Carol Routledge; Martyn Wood
Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat.
Journal of medicinal chemistry 2000;43(9):1878-85.
2000: David R Thomas; Peter J Atkinson; M Ho; Steven M Bromidge; Peter J Lovell; A J Villani; James Hagan; Derek N Middlemiss; Gary W Price
[(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors.
British journal of pharmacology 2000;130(2):409-17.
2000: E Bull; Charlie Reavill; James Hagan; Philip Overend; Declan N C Jones
Evaluation of the spontaneously hypertensive rat as a model of attention deficit hyperactivity disorder: acquisition and performance of the DRL-60s test.
Behavioural brain research 2000;109(1):27-35.
2000: Peter J Lovell; Steven M Bromidge; S Dabbs; DM Duckworth; Ian T Forbes; AJ Jennings; Frank D King; Derek N Middlemiss; S K Rahman; DV Saunders; L L Collin; James Hagan; Graham J Riley; David R Thomas
A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).
Journal of medicinal chemistry 2000;43(3):342-5.
2000: James Hagan; Alex J Harper; H Elliott; Declan N C Jones; Derek C Rogers
Practical and theoretical issues in gene-targeting studies and their application to behaviour.
Reviews in the neurosciences 2000;11(1):3-13.
1999: Derek C Rogers; Declan N C Jones; P R Nelson; C M Jones; C A Quilter; T L Robinson; James Hagan
Use of SHIRPA and discriminant analysis to characterise marked differences in the behavioural phenotype of six inbred mouse strains.
Behavioural brain research 1999;105(2):207-17.
1999: James Hagan; Ronald A Leslie; S Patel; ML Evans; T A Wattam; S Holmes; Christopher D Benham; SG Taylor; Carol Routledge; P Hemmati; Richard Munton; Tracey E Ashmeade; A S Shah; Jonathan P Hatcher; Paula D Hatcher; Declan N C Jones; Martin I Smith; DC Piper; A Jackie Hunter; Rod A Porter; Neil Upton
Orexin A activates locus coeruleus cell firing and increases arousal in the rat.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(19):10911-6.
1999: Martin Coldwell; Izzy Boyfield; T Brown; James Hagan; Derek N Middlemiss
Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.
British journal of pharmacology 1999;127(7):1696-702.
1999: Declan N C Jones; Rudie Kortekaas; Paula D Hatcher; Derek N Middlemiss; A White; James Hagan
Influence of peptide CRF receptor antagonists upon the behavioural effects of human/rat CRF.
European journal of pharmacology 1999;373(2-3):141-5.
1998: Laramie M Gaster; P Ham; GF Joiner; Frank D King; KR Mulholland; Paul A Wyman; James Hagan; Gary W Price; Claire Roberts; Carol Routledge; Julie V Selkirk; P D Slade; Derek N Middlemiss
The selective 5-HT1B receptor inverse agonist SB-224289, potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo.
Annals of the New York Academy of Sciences 1998;861():270-1.
1998: Jonathan P Hatcher; James Hagan
The effects of dopamine D3/D2 receptor agonists on intracranial self stimulation in the rat.
Psychopharmacology 1998;140(4):405-10.
1998: Jonathan P Hatcher; JM Loudon; James Hagan; MS Clark
Sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, reverses delay-induced deficits in the T-maze.
Psychopharmacology 1998;138(3-4):275-82.
1998: Jackie Cilia; DC Piper; Neil Upton; James Hagan
A comparison of rectal and subcutaneous body temperature measurement in the common marmoset.
Journal of pharmacological and toxicological methods 1998;40(1):21-6.
1998: Declan N C Jones; Rudie Kortekaas; P D Slade; Derek N Middlemiss; James Hagan
The behavioural effects of corticotropin-releasing factor-related peptides in rats.
Psychopharmacology 1998;138(2):124-32.
1998: Laramie M Gaster; Frank E Blaney; S Davies; DM Duckworth; P Ham; S Jenkins; AJ Jennings; GF Joiner; Frank D King; KR Mulholland; Paul A Wyman; James Hagan; Jonathan P Hatcher; BJ Jones; Derek N Middlemiss; Gary W Price; Graham Riley; Claire Roberts; Carol Routledge; Julie V Selkirk; P D Slade
The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo.
Journal of medicinal chemistry 1998;41(8):1218-35.
1998: Ian T Forbes; S Dabbs; DM Duckworth; AJ Jennings; Frank D King; Peter J Lovell; AM Brown; LJ Collin; James Hagan; Derek N Middlemiss; Graham J Riley; David R Thomas; Neil Upton
(R)-3,N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl) propyl]benzenesulfonamide: the first selective 5-HT7 receptor antagonist.
Journal of medicinal chemistry 1998;41(5):655-7.
1997: James Hagan; Jonathan P Hatcher
Revised CMS model.
Psychopharmacology 1997;134(4):354-6; discussion 371-7.
1997: James Hagan; P D Slade; Laramie M Gaster; Phillip Jeffrey; Jonathan P Hatcher; Derek N Middlemiss
Stimulation of 5-HT1B receptors causes hypothermia in the guinea pig.
European journal of pharmacology 1997;331(2-3):169-74.
1997: James Hagan; D N Middlemiss; P C Sharpe; G H Poste
Parkinson's disease: prospects for improved drug therapy.
Trends in pharmacological sciences 1997;18(5):156-63.
1997: Jonathan P Hatcher; D J Bell; T J Reed; James Hagan
Chronic mild stress-induced reductions in saccharin intake depend upon feeding status.
Journal of psychopharmacology (Oxford, England) 1997;11(4):331-8.
1996: Izzy Boyfield; T H Brown; Martin Coldwell; D G Cooper; Michael S Hadley; James Hagan; M A Healy; A Johns; R J King; Derek N Middlemiss; David J Nash; Graham J Riley; E E Scott; Stephen A Smith; Geoffrey Stemp
Design and synthesis of 2-naphthoate esters as selective dopamine D4 antagonists.
Journal of medicinal chemistry 1996;39(10):1946-8.
1996: P S Lloyd; P D Slade; Jonathan P Hatcher; James Hagan
A computer-controlled apparatus for measuring and analysing myoclonic jerk activity in guinea pigs.
Journal of neuroscience methods 1996;64(2):253-62.
1995: James Hagan; Jonathan P Hatcher; P D Slade
The role of 5-HT1D and 5-HT1A receptors in mediating 5-hydroxytryptophan induced myoclonic jerks in guinea pigs.
European journal of pharmacology 1995;294(2-3):743-51.
1995: P P Rompré; R Injoyan; James Hagan
Effects of granisetron, a 5-HT3 receptor antagonist, on morphine-induced potentiation of brain stimulation reward.
European journal of pharmacology 1995;287(3):263-9.
1992: James Hagan; E E Verheijck; M H Spigt; G S Ruigt
Behavioural and electrophysiological studies of entorhinal cortex lesions in the rat.
Physiology & behavior 1992;51(2):255-66.
1991: Michael Tweedle; James Hagan; K Kumar; S Mantha; C A Chang
Reaction of gadolinium chelates with endogenously available ions.
Magnetic resonance imaging 1991;9(3):409-15.
1991: M G Van Luijtelaar; J A Tonnaer; A L Frankhuijzen; H Dijkstra; James Hagan; H W Steinbusch
Morphological, neurochemical, and behavioral studies on serotonergic denervation and graft-induced reinnervation of the rat hippocampus.
Neuroscience 1991;42(2):365-77.
1990: James Hagan; M Beaughard
The effects of forebrain ischaemia on spatial learning.
Behavioural brain research 1990;41(2):151-60.
1990: James Hagan; J H Jansen; F E Nefkens; T de Boer
Therapeutic effect of THA on hemicholinium-3-induced learning impairment is independent of serotonergic and noradrenergic systems.
Psychopharmacology 1990;101(3):376-83.
1989: James Hagan; J H Jansen; C L E Broekkamp
Hemicholinium-3 impairs spatial learning and the deficit is reversed by cholinomimetics.
Psychopharmacology 1989;98(3):347-56.
1988: James Hagan; B van der Heijden; C L E Broekkamp
The relative potencies of cholinomimetics and muscarinic antagonists on the rat iris in vivo: effects of pH on potency of pirenzepine and telenzepine.
Naunyn-Schmiedeberg's archives of pharmacology 1988;338(5):476-83.
1988: James Hagan; J H Jansen; C L E Broekkamp
Selective behavioural impairment after acute intoxication with trimethyltin (TMT) in rats.
Neurotoxicology 1988;9(1):53-74.
1988: James Hagan; J D Salamone; J Simpson; S D Iversen; R G Morris
Place navigation in rats is impaired by lesions of medial septum and diagonal band but not nucleus basalis magnocellularis.
Behavioural brain research 1988;27(1):9-20.
1987: R G Morris; James Hagan; Lynn Nadel; J Jensen; Michel Baudry; G S Lynch
Spatial learning in the rat: impairment induced by the thiol-proteinase inhibitor, leupeptin, and an analysis of [3H]glutamate receptor binding in relation to learning.
Behavioral and neural biology 1987;47(3):333-45.
1987: James Hagan; J A Tonnaer; H Rijk; C L E Broekkamp; A M van Delft
Facilitation of amphetamine-induced rotation by muscarinic antagonists is correlated with M2 receptor affinity.
Brain research 1987;410(1):69-73.
1987: James Hagan; J A Tonnaer; C L E Broekkamp
Cholinergic stimulation of drinking from the lateral hypothalamus: indications for M2 muscarinic receptor mediation.
Pharmacology, biochemistry, and behavior 1987;26(4):771-9.
1987: James Hagan; J H Jansen; C L E Broekkamp
Blockade of spatial learning by the M1 muscarinic antagonist pirenzepine.
Psychopharmacology 1987;93(4):470-6.
1986: R G Morris; James Hagan; J N Rawlins
Allocentric spatial learning by hippocampectomised rats: a further test of the "spatial mapping" and "working memory" theories of hippocampal function.
The Quarterly journal of experimental psychology. B, Comparative and physiological psychology 1986;38(4):365-95.
1986: James Hagan; F Tweedie; R G Morris
Lack of task specificity and absence of posttraining effects of atropine on learning.
Behavioral neuroscience 1986;100(4):483-93.
1984: James Hagan; B Bohus
Vasopressin prolongs bradycardiac response during orientation.
Behavioral and neural biology 1984;41(1):77-83.
1983: James Hagan
Post training lysine-vasopressin injections increase conditioned suppression in rats.
Physiology & behavior 1983;31(6):765-9.
1983: James Hagan; B Bohus
The effects of endorphins on cardiac responses during an emotional stress.
Physiology & behavior 1983;31(5):607-14.
1983: James Hagan; J E Alpert; R G Morris; S D Iversen
The effects of central catecholamine depletions on spatial learning in rats.
Behavioural brain research 1983;9(1):83-104.
1983: James Hagan; D J Balfour
Lysine vasopressin fails to alter (3H)-noradrenaline uptake or release from hippocampal tissue in vitro.
Life sciences 1983;32(22):2517-22.
1983: I C Dewhurst; James Hagan; R G Morris; R Griffiths
Hippocampal electrical activity and gamma-aminobutyrate metabolism in brain tissue following administration of homocysteine.
Journal of neurochemistry 1983;40(3):752-7.
1982: James Hagan; B Bohus; D de Wied
Post-training vasopressin injections may facilitate or delay shuttle-box avoidance extinction.
Behavioral and neural biology 1982;36(3):211-28.
1982: James Hagan
Effects of lysine vasopressin and response prevention on avoidance responding in extinction.
Behavioral and neural biology 1982;36(2):204-10.